Abstract YO12
Case summary
Case report : Hepatic EBV-associated Smooth Muscle Tumor (EBV-SMT)
A 51-year-old Thai man with history of HIV infection and chronic HBV hepatitis was sent to Vajira Hospital to evaluate liver lesions. He once had had pulmonary tuberculosis that was properly treated. Two years ago, the liver masses had been first identified on ultrasonography obtained routinely for HCC surveillance. At that moment, he was asymptomatic. His blood counts and blood chemistries including serum AFP were all unremarkable.
The triple-phase CT scan demonstrated two peripheral arterial enhancing masses with progressively enhanced on porto-venous and delayed phases, measured 5.7x4.7 cm and 4.2x3.4cm at segment IVa and IVb, respectively. Another enhancing nodule at porto-venous phase with decreased enhancement at delayed phase was found at segment V. Hepatic hemangioma had been considered and he had been advised to be closely observed, until three months ago, the repeated CT scan showed increasing size of the liver lesion at segment IVa to 6.0x4.7x5.1 cm, the rests were still stable in size.
At Vajira Hospital, he looked healthy. Physical examination was unrevealing. His blood count is normal. His blood chemistries were remarkable for mild elevation of ALT (194 U/L) (normal level, 46-116 U/L). His latest CD4 count and HIV viral load collected on 27/2/60 were 244/mm3 and less than 40 copies/mL, respectively. He was taking TDF/FTC/EFV.
MRI of upper abdomen revealed three progressively heterogeneously enhancing liver masses at segment at segment IVa, IVb, and V. The largest one was about 7.0x4.5x5.2 cm. The masses were in proximity of the left and middle hepatic veins. Percutaneous biopsy under CT guidance was done. It reported atypical spindle cell proliferation. IHC staining were positive for SMA and EBER, but negative for CD31, CD34, ERG, FLI-1, HHV-8, and Desmin. Thereby, EBV-SMT was diagnosed.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract